Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

Abstract Background Emerging evidence supports the diagnostic and prognostic utility of plasma biomarkers in Alzheimer’s disease (AD), particularly in early disease stages. We sought to extend these findings by evaluating the prognostic value of plasma biomarkers in a clinical trial of mild-to-moder...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James B. Brewer, Gabriel C. Léger, Brianna Askew, Lia Donahue, Stephen Kaplita, Vladimir Coric, Irfan A. Qureshi, Howard H. Feldman, The Alzheimer’s Disease Cooperative Study T2 Protect AD Study Group
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Alzheimer’s Research & Therapy
Online Access:https://doi.org/10.1186/s13195-025-01745-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01745-3

Similar Items